Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Phase II Chemotherapy with Cyclocytidine for Children with Acute Leukemia and Solid Tumors

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Published Results
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Completed under 18 NCI CCG-051

Objectives

I.  Determine the efficacy of cyclocytidine in acute leukemia and solid tumors 
of childhood.
II.  Determine the toxicity and tolerated dose of cyclocytidine.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with acute leukemia or solid 
tumors, who are resistant to standard modalities of therapy including cytosine 
arabinoside (ARA-C), who have a life expectancy of at least 12 weeks.  Bone 
marrow must be M-3 for leukemia patients, solid tumor patients must have 
measurable disease and adequate bone marrow, liver and kidney function.

Expected Enrollment

Protocol closed 02/78 and terminated 10/78.

Outline

Nonrandomized study.
Arm I:  Single-agent Chemotherapy.  Cyclocytidine, CYC, NSC-145668.

Published Results

Finklestein JZ, Higgins G, Krivit W, et al.: Evaluation of cyclocytidine in children with advanced acute leukemia and solid tumors. Cancer Treat Rep 63(8): 1331-1333, 1979.

Trial Contact Information

Trial Lead Organizations

Children's Cancer Group

G. Denman Hammond, MD, Protocol chair(Contact information may not be current)
Ph: 316-268-5000

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.